Restructure Improves Financial Position and Allows Company to Focus on
Clinical Development for HIV-Related Condition and Myotonic Muscular Dystrophy
RICHMOND, VA., March 7 /CNW/ - Insmed Inc., (NASDAQ: INSM) announced
today that it has restructured its operations as a result of the litigation
settlement with Tercica Inc. (NASDAQ: TRCA) and Genentech Inc. (NYSE: DNA),
which was announced yesterday, ending all litigation between the parties.
In its restructuring, Insmed's sales and marketing group will be
eliminated and production at Insmed's manufacturing site in Boulder, Colorado
will be scaled back, to reflect the reduced drug product requirement. The
Company anticipates that the current workforce of 150 will be reduced by
approximately 34% as a result of the restructure. The projected savings are
expected to extend the Company's current cash reserves and allow the Company
to fund its operations into the fourth quarter of 2007. As of December 31,
2006 Insmed had $24.1 million of cash on hand.
Geoffrey Allan Ph. D., President, CEO and Chairman of Insmed, commented:
"With the lawsuit behind us we can now focus all our efforts on developing
IPLEX for the promising indications we have already identified, and with the
License and Development agreement with Tercica and Genentech in place we
believe we are well positioned for success." Dr. Allan added that, "The end of
litigation removes a cloud from the Company's future and the consequent
restructuring allows for an improved financial position."
The Company is presently conducting ongoing clinical research in patients
with HIV associated Adipose Redistribution Syndrome (HARS) and Myotonic
Muscular Dystrophy (MMD). The clinical trial for HARS is ongoing at the
University of California, San Francisco while the MMD clinical trial is
ongoing at the University of Rochester. Initial data from both trials is
expected to be released in Q2 2007.
Conference Call Today
The Company will host a conference call on Wednesday, March 7 at 11:00
a.m. (ET) to provide an update on the litigation with Genentech and Tercica,
and other business details.
Among participants on the call will be Geoffrey Allan, president and CEO
of Insmed and Kevin Tully, Executive Vice President and CFO.
Interested investors can listen to the call over the internet from
Insmed's investor relations website at www.insmed.com or by dialing (888)
802-2225 (domestic) or (913) 312-1268 (international).
Insmed Inc. is a biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic diseases
and endocrine disorders with unmet medical needs. For more information about
Insmed or details about the Insmed-Tercica-Genentech settlement, please visit
Insmed's leading product, IPLEX(TM), a complex of recombinant human IGF-I
and its binding protein IGFBP-3, was approved as an orphan drug by the United
States Food and Drug Administration in December 2005. The drug is being
investigated for various indications with unmet medical needs, including
Myotonic Muscular Dystrophy and HIV associated Adipose Redistribution Syndrome
Forward looking statements
Statements included within this press release, which are not historical
in nature, may constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are not limited
to, statements regarding business strategies, results of operations, financial
position, cash flows, financing plans, competitive positions, growth
opportunities for approved or proposed products, plans and objectives of
management. Such forward-looking statements are subject to numerous risks and
uncertainties, including risks that our product candidates may fail in
clinical trials or may not be successfully marketed, we may lack financial
resources to complete development of product candidates, we may be unable to
raise additional financing necessary to continue current operations competing
products may be more successful, demand for new pharmaceutical products may
decrease and the biopharmaceutical industry may experience negative market
trends. As a result of these and other risks and uncertainties, actual results
may differ materially from those described in this press release. For further
information with respect to factors that could cause actual results to differ
from expectations, reference is made to reports filed by the Company with the
Securities and Exchange Commission under the Securities Exchange Act of 1934,
as amended. The forward-looking statements made in this release are made only
as of the date hereof and Insmed disclaims any intention or responsibility for
updating predictions or financial guidance contained in this release.
For further information:
For further information: Investor Relations International Haris Tajyar
Managing Partner 818-382-9702 email@example.com